Natural Product (NP) Details
| General Information of the NP (ID: NP1047) | |||||
|---|---|---|---|---|---|
| Name |
Zerumbone
|
||||
| Synonyms |
Zerumbone; 471-05-6; (2E,6E,10E)-2,6,9,9-tetramethylcycloundeca-2,6,10-trien-1-one; (E,E,E)-2,6,9,9-Tetramethyl-2,6,10-cycloundecatrien-1-one; CHEMBL245412; 2E,6E,9E-humulatrien-8-one; CHEBI:63892; C15H22O; Zerumbone (6CI,7CI); 2,6,9,9-tetramethylcycloundeca-2,6,10-trien-1-one; SCHEMBL12831266; Zerumbone, >=98% (HPLC); HY-N7015; BDBM50241296; MFCD03700769; NSC698299; s5928; ZINC28878195; CCG-208558; NSC-698299; CS-0003365; C20262; Q27132897
Click to Show/Hide
|
||||
| Species Origin | Zingiber zerumbet ... | Click to Show/Hide | |||
| Zingiber zerumbet | |||||
| Disease | Breast cancer [ICD-11: 2C60] | Investigative | [1] | ||
| Structure |
|
Click to Download Mol2D MOL |
|||
| ADMET Property |
Absporption
Caco-2 Permeability
-4.643
MDCK Permeability
-4.661
PAMPA
- - -
HIA
- -
Distribution
VDss
0.182
PPB
67.5%
BBB
- - -
Metabolism
CYP1A2 inhibitor
+++
CYP1A2 substrate
- - -
CYP2C19 inhibitor
+++
CYP2C19 substrate
- - -
CYP2C9 inhibitor
+
CYP2C9 substrate
- - -
CYP2D6 inhibitor
- - -
CYP2D6 substrate
- - -
CYP3A4 inhibitor
+++
CYP3A4 substrate
- - -
CYP2B6 inhibitor
+++
CYP2B6 substrate
- - -
CYP2C8 inhibitor
+++
HLM Stability
+++
Excretion
CLplasma
9.316
T1/2
0.527
Toxicity
DILI
+++
Rat Oral Acute Toxicity
- - -
FDAMDD
++
Respiratory
++
Human Hepatotoxicity
+++
Ototoxicity
- -
Drug-induced Nephrotoxicity
++
Drug-induced Neurotoxicity
++
Hematotoxicity
- -
Genotoxicity
+++
Tips: 1. For the classification endpoints, the prediction probability values are transformed into six symbols: 0-0.1 (- - -), 0.1-0.3 (- -), 0.3-0.5 (-), 0.5-0.7 (+), 0.7-0.9 (++), and 0.9-1.0 (+++).
2. Additionally, the corresponding relationships of the three labels are as follows: excellent; medium; poor.
Click to Show/Hide
|
||||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
| Formula |
C15H22O
|
||||
| PubChem CID | |||||
| Canonical SMILES |
CC1=CCC(C=CC(=O)C(=CCC1)C)(C)C
|
||||
| InChI |
1S/C15H22O/c1-12-6-5-7-13(2)14(16)9-11-15(3,4)10-8-12/h7-9,11H,5-6,10H2,1-4H3/b11-9+,12-8+,13-7+
|
||||
| InChIKey |
GIHNTRQPEMKFKO-SKTNYSRSSA-N
|
||||
| CAS Number |
CAS 471-05-6
|
||||
| ChEBI ID | |||||
| Herb ID | |||||
| SymMap ID | |||||
| TCMSP ID | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
| Nimesulide | Colorectal cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | COX-2 | Molecule Info |
Pathway MAP
|
|
| In-vivo Model | Colitis was induced in female ICR mice at 7 weeks of age. | |||||
| Experimental
Result(s) |
ZER is a novel food factor for mitigating experimental UC and that use of a combination of agents, with different modes of actions, may be an effective anti-inflammatory strategy. | |||||
| Cisplatin | Bladder cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [3] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| In-vitro Model | HeLa | CVCL_0030 | Endocervical adenocarcinoma | Homo sapiens | ||
| In-vivo Model | Inbred BALB/c mice with CIN were injected peritoneally with isotonic sodium chloride solution (positive control), CIS, ZER, and a combination of both compounds. | |||||
| Experimental
Result(s) |
The combination of ZER and CIS has modulated the serum level of interleukin 6 when compared with that in mice treated with isotonic sodium chloride solution. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Baculoviral IAP repeat-containing 1 (AKT1S1) | Molecule Info | [4] | |
| Caspase-3 (CASP3) | Molecule Info | [4] | ||
| Forkhead box protein O1A (FOXO1) | Molecule Info | [4] | ||
| KEGG Pathway | MAPK signaling pathway | Click to Show/Hide | ||
| 2 | p53 signaling pathway | |||
| 3 | Apoptosis | |||
| 4 | Natural killer cell mediated cytotoxicity | |||
| 5 | TNF signaling pathway | |||
| 6 | Serotonergic synapse | |||
| 7 | Non-alcoholic fatty liver disease (NAFLD) | |||
| 8 | Alzheimer's disease | |||
| 9 | Parkinson's disease | |||
| 10 | Amyotrophic lateral sclerosis (ALS) | |||
| 11 | Huntington's disease | |||
| 12 | Epithelial cell signaling in Helicobacter pylori infection | |||
| 13 | Pertussis | |||
| 14 | Legionellosis | |||
| 15 | Toxoplasmosis | |||
| 16 | Amoebiasis | |||
| 17 | Tuberculosis | |||
| 18 | Hepatitis B | |||
| 19 | Herpes simplex infection | |||
| 20 | Pathways in cancer | |||
| 21 | Viral carcinogenesis | |||
| 22 | Proteoglycans in cancer | |||
| 23 | MicroRNAs in cancer | |||
| 24 | Colorectal cancer | |||
| 25 | Viral myocarditis | |||
| 26 | FoxO signaling pathway | |||
| 27 | AMPK signaling pathway | |||
| 28 | Insulin signaling pathway | |||
| 29 | Thyroid hormone signaling pathway | |||
| 30 | Glucagon signaling pathway | |||
| 31 | Transcriptional misregulation in cancer | |||
| 32 | Prostate cancer | |||
| NetPath Pathway | TCR Signaling Pathway | Click to Show/Hide | ||
| 2 | IL2 Signaling Pathway | |||
| 3 | IL4 Signaling Pathway | |||
| Panther Pathway | Apoptosis signaling pathway | Click to Show/Hide | ||
| 2 | FAS signaling pathway | |||
| 3 | Huntington disease | |||
| 4 | CCKR signaling map ST | |||
| 5 | Insulin/IGF pathway-protein kinase B signaling cascade | |||
| 6 | PI3 kinase pathway | |||
| Pathway Interaction Database | LPA receptor mediated events | Click to Show/Hide | ||
| 2 | Calcineurin-regulated NFAT-dependent transcription in lymphocytes | |||
| 3 | FAS (CD95) signaling pathway | |||
| 4 | Role of Calcineurin-dependent NFAT signaling in lymphocytes | |||
| 5 | Posttranslational regulation of adherens junction stability and dissassembly | |||
| 6 | p75(NTR)-mediated signaling | |||
| 7 | HIV-1 Nef: Negative effector of Fas and TNF-alpha | |||
| 8 | Caspase Cascade in Apoptosis | |||
| 9 | Syndecan-2-mediated signaling events | |||
| 10 | Regulation of nuclear SMAD2/3 signaling | |||
| 11 | Signaling events mediated by HDAC Class III | |||
| 12 | Angiopoietin receptor Tie2-mediated signaling | |||
| 13 | CXCR4-mediated signaling events | |||
| 14 | FoxO family signaling | |||
| 15 | Regulation of Androgen receptor activity | |||
| 16 | IL6-mediated signaling events | |||
| 17 | Class I PI3K signaling events mediated by Akt | |||
| Reactome | SMAC binds to IAPs | Click to Show/Hide | ||
| 2 | SMAC-mediated dissociation of IAP:caspase complexes | |||
| 3 | Apoptotic cleavage of cellular proteins | |||
| 4 | Degradation of the extracellular matrix | |||
| 5 | NADE modulates death signalling | |||
| 6 | Activation of DNA fragmentation factor | |||
| 7 | Caspase-mediated cleavage of cytoskeletal proteins | |||
| 8 | AKT phosphorylates targets in the nucleus | |||
| 9 | Regulation of gene expression in beta cells | |||
| 10 | AKT-mediated inactivation of FOXO1A | |||
| 11 | Constitutive Signaling by AKT1 E17K in Cancer | |||
| 12 | MAPK6/MAPK4 signaling | |||
| WikiPathways | DNA Damage Response | Click to Show/Hide | ||
| 2 | SIDS Susceptibility Pathways | |||
| 3 | Apoptosis Modulation by HSP70 | |||
| 4 | MAPK Signaling Pathway | |||
| 5 | Copper homeostasis | |||
| 6 | FAS pathway and Stress induction of HSP regulation | |||
| 7 | Signaling by Hippo | |||
| 8 | Apoptosis | |||
| 9 | Amyotrophic lateral sclerosis (ALS) | |||
| 10 | Spinal Cord Injury | |||
| 11 | BDNF signaling pathway | |||
| 12 | Integrated Pancreatic Cancer Pathway | |||
| 13 | Oncostatin M Signaling Pathway | |||
| 14 | Parkinsons Disease Pathway | |||
| 15 | Corticotropin-releasing hormone | |||
| 16 | Allograft Rejection | |||
| 17 | AGE/RAGE pathway | |||
| 18 | TNF alpha Signaling Pathway | |||
| 19 | Prostate Cancer | |||
| 20 | Alzheimers Disease | |||
| 21 | TWEAK Signaling Pathway | |||
| 22 | Integrated Breast Cancer Pathway | |||
| 23 | Signalling by NGF | |||
| 24 | Integrated Cancer pathway | |||
| 25 | Regulation of Apoptosis | |||
| 26 | Intrinsic Pathway for Apoptosis | |||
| 27 | Apoptotic execution phase | |||
| 28 | Apoptosis Modulation and Signaling | |||
| 29 | miRNA Regulation of DNA Damage Response | |||
| 30 | ErbB Signaling Pathway | |||
| 31 | Insulin Signaling | |||
| 32 | EGF/EGFR Signaling Pathway | |||
| 33 | Pregnane X Receptor pathway | |||
| 34 | Endoderm Differentiation | |||
| 35 | Adipogenesis | |||
| 36 | B Cell Receptor Signaling Pathway | |||
| 37 | Signaling Pathways in Glioblastoma | |||
| 38 | FSH signaling pathway | |||
| 39 | Leptin signaling pathway | |||
| 40 | Regulation of beta-cell development | |||
| 41 | Androgen receptor signaling pathway | |||